{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:35:20Z","timestamp":1790487320010,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["MPY110\/18"],"award-info":[{"award-number":["MPY110\/18"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["DTS18CIII\/00006"],"award-info":[{"award-number":["DTS18CIII\/00006"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["MPY127\/19"],"award-info":[{"award-number":["MPY127\/19"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17CIII-00014"],"award-info":[{"award-number":["PI17CIII-00014"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Microbiology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.tim.2020.04.003","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T10:36:31Z","timestamp":1590057391000},"page":"900-912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Role of Neutralizing Antibodies in CMV Infection: Implications for New Therapeutic Approaches"],"prefix":"10.1016","volume":"28","author":[{"given":"Virginia","family":"Sandon\u00eds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00e9fani","family":"Garc\u00eda-R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"P\u00e9rez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tim.2020.04.003_bb0005","series-title":"Human Cytomegalovirus. Current Topics in Microbiology and Immunology","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-540-77349-8_1","article-title":"Human cytomegalovirus genome","volume":"vol. 325","author":"Murphy","year":"2008"},{"key":"10.1016\/j.tim.2020.04.003_bb0010","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2020.04.003_bb0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000322141","article-title":"Human cytomegalovirus (HCMV) \u2013 revised","volume":"37","author":"Seitz","year":"2010","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.tim.2020.04.003_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.02392-16","article-title":"Congenital human cytomegalovirus immunity","volume":"91","author":"Britt","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0025","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1172\/JCI90599","article-title":"Immunotherapy for transplantation-associated viral infections","volume":"127","author":"Roddie","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tim.2020.04.003_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1469-0691.2007.01895.x","article-title":"Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy","volume":"14","author":"Kuo","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.tim.2020.04.003_bb0035","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(04)16500-8","article-title":"Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy","volume":"363","author":"Deayton","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2020.04.003_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-018-3195-5","article-title":"Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: A systematic review and meta-analysis","volume":"18","author":"Li","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13643-016-0303-8","article-title":"Impact of cytomegalovirus reactivation on clinical outcomes in immunocompetent critically ill patients: protocol for a systematic review and meta-analysis","volume":"5","author":"Lachance","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.tim.2020.04.003_bb0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jinf.2017.05.020","article-title":"CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy","volume":"75","author":"Mena-Romo","year":"2017","journal-title":"J. Infect."},{"key":"10.1016\/j.tim.2020.04.003_bb0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jinf.2016.02.008","article-title":"Use of antibodies neutralizing epithelial cell infection to diagnose patients at risk for CMV disease after transplantation","volume":"72","author":"Blanco-Lobo","year":"2016","journal-title":"J. Infect."},{"key":"10.1016\/j.tim.2020.04.003_bb0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.TP.0000438025.96334.eb","article-title":"Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant","volume":"97","author":"L\u00f3pez-Oliva","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.tim.2020.04.003_bb0065","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.4049\/jimmunol.1800171","article-title":"Cytomegalovirus: shape-shifting the immune system","volume":"200","author":"Picarda","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2020.04.003_bb0070","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2020.04.003_bb0075","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V98.3.754","article-title":"Differentiation of cytomegalovirus-specific CD8+ T cells in healthy and immunosuppressed virus carriers","volume":"98","author":"Gamadia","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.tim.2020.04.003_bb0080","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1097\/00007890-200105150-00018","article-title":"Correlate with cytomegalovirus control and predict-induced disease after renal transplantation","volume":"71","author":"Sester","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.tim.2020.04.003_bb0085","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/bmt.2008.403","article-title":"Early reconstitution of effector memory CD4+ CMV\u2013specific T cells protects against CMV reactivation following allogeneic SCT","volume":"43","author":"Pourgheysari","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.tim.2020.04.003_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106044","article-title":"Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients","volume":"9","author":"Gabanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tim.2020.04.003_bb0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.transproceed.2013.07.070","article-title":"Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients","volume":"46","author":"D\u00edaz","year":"2014","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.tim.2020.04.003_bb0100","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/jmv.25225","article-title":"Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients","volume":"90","author":"Lilleri","year":"2018","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0105","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1099\/vir.0.000203","article-title":"Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting","volume":"96","author":"Gim\u00e9nez","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.aat0066","article-title":"Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation","volume":"363","author":"Martins","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.tim.2020.04.003_bb0115","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1128\/JVI.01500-15","article-title":"Viral regulation of cell tropism in human cytomegalovirus","volume":"90","author":"Li","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0120","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.tim.2012.04.008","article-title":"Viral and host control of cytomegalovirus maturation","volume":"20","author":"Tandon","year":"2012","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.tim.2020.04.003_bb0125","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1128\/JVI.01141-14","article-title":"Identification of human cytomegalovirus genes important for biogenesis of the cytoplasmic virion assembly complex","volume":"88","author":"Das","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0130","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1073\/pnas.1424818112","article-title":"Structural and biochemical studies of HCMV gH\/gL\/gO and pentamer reveal mutually exclusive cell entry complexes","volume":"112","author":"Ciferri","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2020.04.003_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/v10120704","article-title":"Pathogen at the gates: Human cytomegalovirus entry and cell tropism","volume":"10","author":"Nguyen","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.tim.2020.04.003_bb0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coviro.2018.05.004","article-title":"From recognition to execution \u2013 the HCMV pentamer from receptor binding to fusion triggering","volume":"31","author":"Malito","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0145","first-page":"1","article-title":"Crystal structure of the human cytomegalovirus glycoprotein B","volume":"11","author":"Burke","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2020.04.003_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002999","article-title":"Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies","volume":"8","author":"Kropff","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2020.04.003_bb0155","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1128\/jvi.66.3.1761-1764.1992","article-title":"A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope","volume":"66","author":"Kari","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0160","doi-asserted-by":"crossref","first-page":"8999","DOI":"10.1128\/JVI.01325-15","article-title":"Human cytomegalovirus gH\/gL\/gO promotes the fusion step of entry into all cell types, whereas gH\/gL\/UL128-131 broadens virus tropism through a distinct mechanism","volume":"89","author":"Zhou","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0165","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1128\/JVI.01875-15","article-title":"Scanning mutagenesis of human cytomegalovirus glycoprotein gH\/gL","volume":"90","author":"Schultz","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0170","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1128\/JVI.02249-09","article-title":"A human cytomegalovirus gO-Null mutant fails to incorporate gH\/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells","volume":"84","author":"Wille","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0175","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1128\/JVI.02256-09","article-title":"Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH\/gL incorporation into virions but is not present in virions","volume":"84","author":"Ryckman","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/JVI.01910-07","article-title":"Characterization of the human cytomegalovirus gH\/gL\/UL128-131 complex that mediates entry into epithelial and endothelial cells","volume":"82","author":"Ryckman","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0185","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1086\/605633","article-title":"Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease","volume":"49","author":"Manuel","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2012.01.001","article-title":"Human cytomegalovirus entry into cells Adam","volume":"2","author":"Vanarsdall","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0195","first-page":"1","article-title":"Human cytomegalovirus (HCMV) infection\/re-infection: Development of a protective HCMV vaccine","volume":"42","author":"Gerna","year":"2019","journal-title":"New Microbiol."},{"key":"10.1016\/j.tim.2020.04.003_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1006273","article-title":"A derivative of platelet-derived growth factor receptor alpha binds to the trimer of human cytomegalovirus and inhibits entry into fibroblasts and endothelial cells","volume":"13","author":"Stegmann","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2020.04.003_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1006281","article-title":"Human cytomegalovirus glycoprotein complex gH\/gL\/gO uses PDGFR-\u03b1 as a key for entry","volume":"13","author":"Wu","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2020.04.003_bb0210","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature07209","article-title":"Platelet-derived growth factor-\u03b1 receptor activation is required for human cytomegalovirus infection","volume":"455","author":"Soroceanu","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.tim.2020.04.003_bb0215","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nmicrobiol.2016.82","article-title":"Platelet-derived growth factor-\u03b1 receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer","volume":"1","author":"Kabanova","year":"2017","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.tim.2020.04.003_bb0220","doi-asserted-by":"crossref","first-page":"15470","DOI":"10.1073\/pnas.0406821101","article-title":"Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain","volume":"101","author":"Feire","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2020.04.003_bb0225","doi-asserted-by":"crossref","first-page":"9766","DOI":"10.1128\/JVI.01092-16","article-title":"Cell surface THY-1 contributes to human cytomegalovirus entry via a macropinocytosis-like process","volume":"90","author":"Li","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1004999","article-title":"THY-1 cell surface antigen (CD90) has an important role in the Initial stage of human cytomegalovirus infection","volume":"11","author":"Li","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2020.04.003_bb0235","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.cell.2018.06.028","article-title":"An unbiased screen for human cytomegalovirus identifies neuropilin-2 as a central viral receptor","volume":"174","author":"Martinez-Martin","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.tim.2020.04.003_bb0240","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1073\/pnas.1814850116","article-title":"OR14I1 is a receptor for the human cytomegalovirus pentameric complex and defines viral epithelial cell tropism","volume":"116","author":"Xiaofei","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2020.04.003_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.00781-18","article-title":"CD147 Promotes entry of pentamer-expressing human cytomegalovirus into epithelial and endothelial cells","volume":"9","author":"Vanarsdall","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.tim.2020.04.003_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10587-1","article-title":"CD46 facilitates entry and dissemination of human cytomegalovirus","volume":"10","author":"Stein","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tim.2020.04.003_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v9090249","article-title":"Die another day: Inhibition of cell death pathways by cytomegalovirus","volume":"9","author":"Brune","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.tim.2020.04.003_bb0260","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.4049\/jimmunol.177.10.7094","article-title":"Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells","volume":"177","author":"Boehme","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.tim.2020.04.003_bb0265","doi-asserted-by":"crossref","first-page":"31268","DOI":"10.1074\/jbc.M113.462341","article-title":"Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL","volume":"288","author":"Kaiser","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tim.2020.04.003_bb0270","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/v1030523","article-title":"Activation of the antiviral kinase PKR and viral countermeasures","volume":"1","author":"Dauber","year":"2009","journal-title":"Viruses"},{"key":"10.1016\/j.tim.2020.04.003_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.00194","article-title":"CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function","volume":"8","author":"Takeuchi","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tim.2020.04.003_bb0280","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nri1254","article-title":"Human CD8+ T-cell differentiation in response to viruses","volume":"3","author":"van Lier","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tim.2020.04.003_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep19227","article-title":"Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4+ and CD8+ T-cell responses in older adults positively correlates with response size","volume":"6","author":"Chiu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tim.2020.04.003_bb0290","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1128\/JVI.00121-16","article-title":"Monoclonal antibodies to different components of the human cytomegalovirus (HCMV) pentamer gH\/gL\/pUL128L and trimer gH\/gL\/gO as well as antibodies elicited during primary HCMV infection prevent epithelial cell syncytium formation","volume":"90","author":"Gerna","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0295","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s10875-012-9739-3","article-title":"Antibodies against neutralization epitopes of human cytomegalovirus gH\/gL\/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo","volume":"32","author":"Lilleri","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.tim.2020.04.003_bb0300","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: Antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tim.2020.04.003_bb0305","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.micinf.2009.07.010","article-title":"Recombinant human monoclonal antibodies to human cytomegalovirus glycoprotein B neutralize virus in a complement-dependent manner","volume":"11","author":"Ohta","year":"2009","journal-title":"Microbes Infect."},{"key":"10.1016\/j.tim.2020.04.003_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-017-0038-0","article-title":"Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (Gb) and immune sera induced by Gb\/MF59 vaccination \/631\/250\/590\/2294 \/692\/53\/2423 article","volume":"2","author":"Li","year":"2017","journal-title":"npj Vaccines"},{"key":"10.1016\/j.tim.2020.04.003_bb0315","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1016\/j.vaccine.2018.08.054","article-title":"Analysis of relationships between polymorphisms in the genes encoding the pentameric complex and neutralization of clinical cytomegalovirus isolates","volume":"36","author":"Kobayashi","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2020.04.003_bb0320","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/vir.0.83523-0","article-title":"Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial\/epithelial cells, but not fibroblasts, early during primary infection","volume":"89","author":"Gerna","year":"2008","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0325","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1016\/j.vaccine.2018.07.056","article-title":"Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response","volume":"36","author":"Cui","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2020.04.003_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0059863","article-title":"Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH\/gL\/pUL128-130-131 complex during primary infection","volume":"8","author":"Lilleri","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tim.2020.04.003_bb0335","doi-asserted-by":"crossref","first-page":"11884","DOI":"10.1128\/JVI.01701-15","article-title":"Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH\/gL pentamer potently block primary cytotrophoblast infection","volume":"89","author":"Chiuppesi","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0340","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1814835116","article-title":"HCMV trimer- and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission","volume":"116","author":"Vanarsdall","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2020.04.003_bb0345","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/v6031346","article-title":"HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex","volume":"6","author":"Zydek","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.tim.2020.04.003_bb0350","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/vaccines7040135","article-title":"Neutralizing monoclonal antibodies reduce human cytomegalovirus infection and spread in developing placentas","volume":"7","author":"Tabata","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.tim.2020.04.003_bb0355","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJMoa043337","article-title":"Passive immunization during pregnancy for congenital cytomegalovirus infection","volume":"353","author":"Nigro","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2020.04.003_bb0360","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/TP.0b013e318224115e","article-title":"Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations","volume":"92","author":"Planitzer","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.tim.2020.04.003_bb0365","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/cid\/cis423","article-title":"Early primary cytomegalovirus infection in pregnancy: Maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age","volume":"55","author":"Visentin","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0370","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1515\/jpm-2011-0257","article-title":"Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: A retrospective analysis","volume":"40","author":"Buxmann","year":"2012","journal-title":"J. Perinat. Med."},{"key":"10.1016\/j.tim.2020.04.003_bb0375","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1093\/cid\/cit586","article-title":"Hyperimmunoglobulin for prevention of congenital cytomegalovirus disease","volume":"57","author":"Nigro","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0380","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/cis425","article-title":"Primary maternal cytomegalovirus infection during pregnancy: Do we have a treatment option?","volume":"55","author":"Adler","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0385","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2020.04.003_bb0390","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-0012.2007.00750.x","article-title":"CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis","volume":"22","author":"Bonaros","year":"2008","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.tim.2020.04.003_bb0395","doi-asserted-by":"crossref","first-page":"E455","DOI":"10.1111\/j.1399-0012.2011.01459.x","article-title":"The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the Scientific Registry of Transplant Recipients (SRTR) database","volume":"25","author":"Snydman","year":"2011","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.tim.2020.04.003_bb0400","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26420","article-title":"The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients","volume":"64","author":"Goldstein","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.tim.2020.04.003_bb0405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00430-018-0558-x","article-title":"Role of pentamer complex-specific and IgG subclass 3 antibodies in HCMV hyperimmunoglobulin and standard intravenous IgG preparations","volume":"208","author":"Schampera","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.tim.2020.04.003_bb0410","doi-asserted-by":"crossref","first-page":"17965","DOI":"10.1073\/pnas.1415310111","article-title":"Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies","volume":"111","author":"Kabanova","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2020.04.003_bb0415","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0420","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1086\/421999","article-title":"Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee","volume":"39","author":"Modlin","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0425","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus","volume":"37","author":"Plotkin","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2020.04.003_bb0430","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.20040613","article-title":"Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers","volume":"202","author":"Cobbold","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tim.2020.04.003_bb0435","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cmi.2018.09.019","article-title":"Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study","volume":"25","author":"Molina-Ortega","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.tim.2020.04.003_bb0440","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14760584.2018.1526085","article-title":"A fifty-year odyssey: Prospects for a cytomegalovirus vaccine in transplant and congenital infection","volume":"17","author":"Diamond","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.tim.2020.04.003_bb0445","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/vaccines7030070","article-title":"Human cytomegalovirus cell tropism and host cell receptors","volume":"7","author":"Gerna","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.tim.2020.04.003_bb0450","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2020.04.003_bb0455","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/vaccines5040039","article-title":"Neutralization of human cytomegalovirus entry into fibroblasts and epithelial cells","volume":"5","author":"Wussow","year":"2017","journal-title":"Vaccines"},{"key":"10.1016\/j.tim.2020.04.003_bb0460","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2020.04.003_bb0465","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2020.04.003_bb0470","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tim.2020.04.003_bb0475","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.tim.2020.04.003_bb0480","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CVI.00268-17","article-title":"Progress toward development of a vaccine against congenital cytomegalovirus infection","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.tim.2020.04.003_bb0490","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2020.04.003_bb0495","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/infdis\/jiy102","article-title":"Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B Vaccine with MF59: anti-AD2 levels correlate with protection from viremia","volume":"217","author":"Baraniak","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0500","first-page":"1","article-title":"Intrahost dynamics of human cytomegalovirus variants acquired by seronegative glycoprotein B vaccinees","volume":"93","author":"Nelson","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0505","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/infdis\/jiz089","article-title":"Original antigenic sin shapes the immunological repertoire evoked by human cytomegalovirus glycoprotein B\/MF59 vaccine in seropositive recipients","volume":"220","author":"Baraniak","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0510","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1073\/pnas.1806420115","article-title":"Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection","volume":"115","author":"Schleiss","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2020.04.003_bb0515","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0520","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1073\/pnas.1316517110","article-title":"Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine","volume":"110","author":"Freed","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tim.2020.04.003_bb0525","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/JVI.80.9.4591-4600.2006","article-title":"Human cytomegalovirus infection elicits a glycoprotein M (gM)\/gN-specific virus-neutralizing antibody response","volume":"80","author":"Shimamura","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2020.04.003_bb0530","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/jiz141","article-title":"Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects","volume":"220","author":"Adler","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2020.04.003_bb0535","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.AID-0009-13","article-title":"Immunotherapeutic approaches to prevent cytomegalovirus-mediated disease","volume":"2","author":"Seedah","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.tim.2020.04.003_bb0540","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1128\/AAC.00523-15","article-title":"Phase 1 randomized, double-blind, placebo-controlled study of RG7667, an anticytomegalovirus combination monoclonal antibody therapy, in healthy adults","volume":"59","author":"Ishida","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2020.04.003_bb0545","doi-asserted-by":"crossref","first-page":"e01794-16","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Trends in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X20300925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X20300925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:09:40Z","timestamp":1778573380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966842X20300925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":109,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0966842X20300925"],"URL":"https:\/\/doi.org\/10.1016\/j.tim.2020.04.003","relation":{},"ISSN":["0966-842X"],"issn-type":[{"value":"0966-842X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Neutralizing Antibodies in CMV Infection: Implications for New Therapeutic Approaches","name":"articletitle","label":"Article Title"},{"value":"Trends in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tim.2020.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}